bufotalin and Sjogren-s-Syndrome

Chronic inflammatory autoimmune disease Sjögren's syndrome (SS) is characterized by the reduced secretion of exocrine glands, suggesting strategies targeting inflammation to be a potential option for SS therapy. Bufotalin, an active constituent of Bufadienolides, exerts potent antitumor effects with unknown effects on autoimmune diseases including SS. This study aims to investigate whether bufotalin possesses therapeutic potentials to SS and the underlying mechanisms. The experimental Sjögren's syndrome (ESS) murine model was constructed by SG-immunization and murine naïve CD4

Topics: Animals; Autoantigens; Bufanolides; Disease Models, Animal; Female; Inflammation Mediators; Mice; Mice, Inbred C57BL; Salivary Glands; Sjogren's Syndrome; Th17 Cells